Tailoring Treatments and Tracking Mutations with Liquid Biopsies Becomes Possible with ddPCR™ Technology
Philadelphia, PA — April 20, 2015 — This week researchers will present new findings using Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, April 18–22. Since Bio-Rad Laboratories introduced its Droplet Digital PCR system in 2012, researchers have been using the technology in oncology research with their objective being to tailor cancer treatments — on a tumor-by-tumor basis — by reading the genetic mutations, amplifications, and rearrangements that make each tumor unique.
Researchers are leveraging the exceptional ability of ddPCR technology to detect a very small amount of variant DNA, specifically oncogenic mutant DNA, quickly, inexpensively, and reliably. From developing a ddPCR-based test that could help physicians guide personalized therapy to tracking tumor mutations that cause drug resistance, researchers from more than a dozen academic institutions and biotech companies will highlight the latest advancements using ddPCR technology in cancer research. To date, more than 200 peer-reviewed studies have employed ddPCR systems, of which more than 20 involve their use in research using a cancer liquid biopsy.
Several of the studies highlighted as posters at the AACR meeting include:
Droplet Digital PCR Provides a More Sensitive Test to Detect Gene Amplifications in Tumors than Next-Generation Sequencing-Based Clinical Methods
Gene amplifications of oncogenes are hallmarks of certain cancer types, which are directly linked to FDA-approved treatments, but tests that can adequately detect these copy number alterations have been limited by DNA quantity and tumor purity and heterogeneity. Furthermore, biopsies stored as formalin-fixed paraffin-embedded (FFPE) samples are notoriously difficult to work with and yield limited amounts of DNA as the samples can easily become degraded. In a joint research venture, TOMA Biosciences in Foster City, CA, and the Intermountain Precision Genomics in Saint George, UT, found that a new ddPCR-based test using FFPE samples, called the Amplinome Test, is more than 10 times more sensitive than next-generation sequencing (NGS) clinical methods in detecting gene amplifications of 12 genes commonly amplified in cancer. The Amplinome Test detected gene amplifications that the NGS method missed.
This poster (#23) will be presented from 1–5 PM on Sunday, April 19, in Section 26.
Tracking Patient Response to Cancer Treatments Is Quick and Simple Using ddPCR Technology
Unfortunately, patients can develop additional mutations within a tumor as a result of cancer treatment, which can lead to drug resistance. Researchers from The UK’s Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London will present findings that use patient blood plasma with ddPCR methods to track the evolution of tumor resistance to treatment with anti-EGFR monoclonal antibodies.
This poster (#12) will be presented from 8–12 PM on Tuesday, April 21, in Section 31.
Multiplexing Detects Multiple Mutations Simultaneously, Maximizing Information Gained from Limited Patient Samples
For high sensitivity measurements of circulating cell-free DNA (cfDNA), scientists are given samples of plasma with extremely small amounts of tumor-derived DNA that they use to determine a patient’s cancer mutations. Multiplexing allows the detection of several mutations in a single reaction. The University of Texas MD Anderson Cancer Center in Houston, TX will present research that shows multiplex testing for KRAS mutations does not sacrifice accuracy, even with volumes of DNA as low as 16 ng. Multiplexing saves time and money and is feasible in samples with small proportions of cancer-derived mutant DNA.
This poster (#10) will be presented from 1–5 PM on Monday, April 20, in Section 21.
Droplet Digital PCR Technology Permits Absolute Counting of Target Molecules
Dawne Shelton, PhD, Bio-Rad, will give a talk that summarizes work covering the use of ddPCR technology in the tracking of cell-free tumor DNA for early detection of tumor DNA in blood as well as the monitoring of patient treatment and disease progression. Dr. Shelton will also highlight how ddPCR technology has been used to detect copy number amplifications of genes commonly associated with cancer, such as MYC, HER2, and EGFR, and for the detection of KRAS mutations using a multiplex screening strategy.
Dawne’s presentation will be held from 2–3 PM on Sunday, April 19, in the Exhibitor Spotlight Theater A.
Bio-Rad will have a booth (#1527) featuring the award-winning QX200™ Droplet Digital PCR System (the QX200 System is the latest in the series). The company will also present its newly introduced PrimePCR™ ddPCR KRAS Screening Multiplex Kit at its booth. The KRAS Multiplex Kit can simultaneously detect the seven most common KRAS mutations that play a critical role in tumorigenesis and are most commonly found in pancreatic, thyroid, colorectal, and lung cancers. Bio-Rad will also highlight the Automated Droplet Generator (AutoDG™), which provides an automated workflow and simplifies the ddPCR workflow.
To learn more about ddPCR technology and applications, please visit Bio-Rad’s ddPCR resource page or ddPCR webinar page for more information.
The QX200 Droplet Digital PCR System and Automated Droplet Generator are for research use only and are not intended for use in diagnostic procedures.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Viresh Patel
Bio-Rad Laboratories, Inc.
925-474-8602
viresh_patel@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 109
kli@chempetitive.com